Press Releases Moderna, Inc.

Equities

MRNA

US60770K1079

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
125 ^USD	-0.47%		+15.77%	+25.69%

May. 03	Jefferies Adjusts Price Target on Moderna to $155 From $125	MT
May. 03	Oppenheimer Adjusts Price Target on Moderna to $163 From $142	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates	May. 03	AQ
Moderna: Q1 Earnings Snapshot	May. 02	AQ
Moderna : 2024 ESCMID (mRNA-1010)	Apr. 30	PU
Moderna : Licenses COVID-19-related Intellectual Property to a Pharmaceutical Company in Japan	Apr. 29	PU
Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress	Apr. 26	AQ
Moderna and OpenAI Collaborate To Advance mRNA Medicine	Apr. 25	AQ
Big pharma giants in English High Court for global Covid dispute	Apr. 24	AQ
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign	Apr. 23	AQ
Moderna : 2024 Proxy Statement	Apr. 16	PU
Africa CDC's Statement On Moderna's Plan to Reassess Commitment to African Vaccine Manufacturing [press release]	Apr. 16	AQ
University of Oregon: Options can lower vaccine hesitancy for COVID-19, other diseases	Apr. 15	AQ
Moderna cancer vaccine shows promise in initial tests; share skyrockets	Apr. 12	AQ
Moderna Pauses Plans to Build Vaccines Facility in Kenya	Apr. 12	AQ
Moderna - Statement on Kenya Manufacturing Facility	Apr. 12	AQ
Moderna : Statement on Kenya Manufacturing Facility	Apr. 11	PU
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	Apr. 09	AQ
Moderna : AACR INT Head & Neck Poster	Apr. 08	PU
MRNA therapy could provide intracellular protein replacement for rare disease	Apr. 05	AQ
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials	Mar. 28	AQ
Blackstone Life Sciences Announces Collaboration to Support Moderna's Influenza Program	Mar. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 10:24 am EDT

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 16, 2024 at 03:31 pm EST